Risk factors
Indivior Pharmaceuticals (INDV) risk factors
Item 1A of every Indivior Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors59 risks18 new23 dropped29 reworded
Indivior restructured operations, incurring $127 million in exit costs while centralizing international focus on Australia, Canada, France, and Germany.
Filed Feb 26, 2026 - FY2024 10-K risk factors64 risks
Indivior faces heavy litigation, reliance on third-party manufacturers, and regulatory scrutiny over controlled substances like buprenorphine. The business is exposed to pricing pressures, potential Medicaid cuts, and international tariff proposals on pharmaceuticals.
Filed Mar 03, 2025